



Daiichi-Sankyo

**Requests for Proposal  
Calls for Continuous  
Grant Submissions**

**Fiscal Year (FY) 2026:**

**April 1, 2026 - March 31, 2027**

**Daiichi Sankyo, Inc.**

**Medical Proficiency Acceleration Center:**

Office of Grants & Education, [OGE-CME\\_US@daiichisankyo.com](mailto:OGE-CME_US@daiichisankyo.com)

Grant Submission Site: <https://daiichisankyo.us/corporate-grants-and-giving>

## Request for Proposal

*Daiichi Sankyo believes education is a source to accelerating best, personalized evidence into clinical practice for the best interest of patient care.* Our commitment is to make grant funding available for independent, fair, balanced, and scientifically accurate medical education initiatives that receive no influence from our organization in submission, design, or implementation. Grant conduct is required to comply with all expected regulatory requirements.

---

*Logistical questions regarding grant submissions can be submitted to [OGE-CME\\_US@daiichisankyo.com](mailto:OGE-CME_US@daiichisankyo.com) and will be channeled to the appropriate therapeutic area grant manager.*



**DAIICHI SANKYO'S GRANTS SUBMISSION SITE CAN BE FOUND AT**  
[HTTPS://GRANTSANDGIVINGPORTAL.DSI.STEETPROCKINC.COM/](https://grantsandgivingportal.dsi.steeproking.com/)



- Effective **Monday, March 2, 2026**, Daiichi Sankyo's Medical Proficiency Acceleration Center will transition to a new grants and sponsorship request system.
- You will be required to register your organization one time before submitting a grant or sponsorship request.
- The prior system will remain open only for access to prior requests that are pending, active/open, or in need of reconciliation. This prior system will eventually fully close, therefore access will be for a limited time.

We provide Grants to eligible educational organizations or advocacy groups for accredited certified Continuing Medical Education (CME), non-CME education, scientific events, clinical scholarships and fellowships, or patient education. All Grants and resulting work are independent of Daiichi Sankyo influence and benefit. Please refer to the Standards of Integrity and Independence published by <https://accme.org/> for more information.



**THIS RFP PACKET IS OUR CALL FOR CONTINUOUS GRANT SUBMISSIONS THROUGHOUT THE 2026 FISCAL YEAR.**

Daiichi Sankyo may further publish **time-limited RFPs** for specific projects aligned to specific external gaps/references as the year progresses. We invite eligible organizations to log into the grant portal for information on currently available Calls and/or RFPs throughout the year.

Submissions for FY2026 may begin immediately upon the dissemination of this packet. We aim to make decisions within 60 days of submission.

*Please note decisions for FY2026 grants will not start until **April 1, 2026**.*



**ALLIANCES AND GENERAL MULTI-SUPPORT STATEMENT**

Daiichi Sankyo encourages multi-support where possible but does not require it, provided all education is independent from supporter influence, fair and balanced. Daiichi Sankyo is in alliance with other industry organizations for several of our therapeutic options. We encourage relevant similar submissions to our alliance partners as well if they make those category selections available. As we are separate organizations, our alliance partners will have the right to make decisions that are appropriate for them. Those decisions will not impact the decisions made by Daiichi Sankyo or vice versa.



**STATEMENT ON PARTNERING ORGANIZATIONS**

If there are any other named organizations within a submitted proposal (i.e. educational partner, advocacy group, healthcare institution, etc.) who will play a role in the design of education, development, or execution, we ask that you secure written confirmation from the organization(s) you intend to partner with and confirm this within the application.

# Therapeutic Areas of Interest

Daiichi Sankyo is dedicated to supporting independent education across various therapeutic areas. The below tables outline key areas of interest. These areas are subject to change at any time but reflect accuracy as of the date of distribution.

## Breast Cancer

	Knowledge	Confidence	Practice Change
HER2+ *	Early <sup>g</sup>	X	X
	Metastatic	X	X
HER2-Low & Ultralow * <sup>g</sup>	X	X	X
TROP2 TNBC * <sup>g</sup>	Early	X	X
	Metastatic	X	X
TROP2 HR+ *	X	X	X

\* In alliance with Astra Zeneca

## Lung Cancer

	Knowledge	Confidence	Practice Change
HER2 Overexpression (OE) ** <sup>^</sup>	X	X	X
HER2 Mutations <sup>^</sup>	X	X	X
TROP2 * <sup>g</sup>	1L nAGA mNSCLC	X	X
	EGFRm mNSCLC	X	X
B7-H3 <sup>†</sup>	X	X	

\* In alliance with Astra Zeneca

<sup>†</sup> In alliance with Merck

<sup>^</sup> HER2 OE and early line HER2 mutations are funding priorities

## Genitourinary (GU) Cancers

	Knowledge	Confidence	Practice Change
HER2 Bladder * <sup>‡g</sup>	X	X	X

\* In alliance with Astra Zeneca

<sup>‡</sup> Submissions welcomed as multi-support or in combination with other HER2 non-breast solid tumors (i.e., gyn, GI [CRC & BRC], HER2 OE)

## Hematologic Cancer

	Knowledge	Confidence	Practice Change
AML		X	X

## Gynecologic (Gyn) Cancers

	Knowledge	Confidence	Practice Change
HER2 Gyn Cancers * <sup>g</sup>	X	X	X
CDH6 Ovarian <sup>†</sup>	X	X	

\* In alliance with Astra Zeneca

<sup>†</sup> In alliance with Merck

## Gastrointestinal (GI) Cancers

	Knowledge	Confidence	Practice Change
HER2 CRC * <sup>‡</sup>	X	X	X
HER2 BTC * <sup>‡</sup>	X	X	X
HER2 Gastric/GEJ *	X	X	X

\* In alliance with Astra Zeneca

<sup>‡</sup> Submissions welcomed as multi-support or in combination with other HER2 non-breast solid tumors (i.e., gyn, GI [CRC & BRC], HER2 OE)

## Tenosynovial Giant Cell Tumor (TGCT)

	Knowledge	Confidence	Practice Change
TGCT	X	X	X

<sup>g</sup> Beginning in FY2026, DSI also welcomes and accepts IME proposals aligned to digital activities to reach global HCP audiences

# IME Symposia of Interest FY2026

## U.S. Based Congresses



Congress	Targets	Submissions Due
<b>ASTRO</b>	HER2+ Breast Cancer	10, April 2026
<b>ASH</b>	FLT3 AML	1, May 2026
<b>JADPRO</b>	AE management of HER2/TROP2/B7-H3 ADCs	8, May 2026
<b>IASLC NA</b>	HER2/TROP2 NSCLC; B7-H3 SCLC	15, May 2026
<b>SABCS</b>	HER2+, HER2-low, TNBC, HR+	15, May 2026
<b>SNO</b>	HER2 management of brain metastases	29, May 2026
<b>SUO</b>	HER2 bladder	1, August 2026
<b>ASCO-GI</b>	HER2 GEJ/GC, CRC, BTC	28, August 2026
<b>ASCO-GU</b>	HER2 bladder	28, August 2026
<b>IASLC/TTLC</b>	HER2/TROP2 NSCLC; B7-H3 SCLC	28, August 2026
<b>USCAP</b>	HER2 solid tumors	11, September 2026
<b>SSO</b>	HER2+ Breast Cancer, TNBC	18, September 2026
<b>SGO</b>	HER2 gyn, CDH6 ovarian	18, September 2026
<b>ASBrS</b>	HER2+ Breast Cancer, TNBC	9, October 2026
<b>AACR</b>	CDH6 ovarian	9, October 2026
<b>HOPA</b>	AE management of HER2/TROP2/B7-H3 ADCs	9, October 2026
<b>ONS</b>	AE management of HER2/TROP2/B7-H3 ADCs	9, October 2026
<b>ASCO</b>	<b>Breast:</b> HER2+, HER2-low, TNBC <b>Lung:</b> B7-H3 SCLC; HER2/TROP2 NSCLC <b>Gyn:</b> CDH6 ovarian, HER2 gyn tumors <b>GI:</b> HER2 GEJ/GC, CRC, BTC <b>Hematology:</b> AML	4, December 2026

## Outside-US (OUS) Based Congresses



At this time, Daiichi Sankyo is still evaluating activities it will support in response to congresses taking place OUS. Daiichi Sankyo will evaluate submissions for IME symposia at OUS congresses on a case-by-case and rolling basis.

Please note that based on the recent decision by EACCME, symposia in Europe may be certified for credit by another reputable/established and accepted accreditor, or non-certified while still respecting the standards of providing independent, fair/balanced, and current information.

The listed are alphabetical examples of OUS congresses where historically Daiichi Sankyo has supported IME symposia. Please note this is not a complete list. We recognize that these congresses may have various requirements surrounding securing a slot for IME/CME symposia, therefore, **we ask that those proposals clearly define those requirements and deadlines.** Daiichi Sankyo will review all proposals received; however, we reserve the right not to proceed with programs for any congress listed.

*(If you choose to submit now it would be advisable that you budget for the congress slot purchase requirement. Should the Daiichi Sankyo Global Medical Affairs slot purchases be confirmed at the time of your potential grant approval, we will reduce the slot amount from the grant award.)*

OUS Congress*	Topics of Interest	Submissions Due
<b>WCLC</b>	HER2 overexpression NSCLC	3, April 2026
<b>ESMO</b>	HER2+ mBC HER2+ solid tumors	10, April 2026
<b>ESMO-Asia</b>	HER2+ GI	5, June 2026
<b>ESMO-Breast</b>	<i>ESMO-Breast 2026 IME already selected</i>	

\* OUS Congresses listed are not exhaustive and Daiichi Sankyo may further publish time-limited RFPs

## Closing Information

All submissions will be reviewed in compliance to our Standard Operating Procedures and Policies, impartially without any preset grant decision(s) made at the release of this packet. Daiichi Sankyo does not support the costs incurred during the preparation of any grant. Daiichi Sankyo publishes Calls for Continuous Grant Submissions/RFPs online through the specific Daiichi Sankyo grants portal. This packet is also posted to the Alliance for Continuing Education for the Health Professions (ACEhp) membership site and further distributed to all educational providers who have previously submitted and completed successful independent medical education activities within a year from the time of this packet dissemination.

Daiichi Sankyo adheres to the commercial support standards established by the Accreditation Council for Continuing Medical Education (ACCME®). The company also complies with the principles established by the Office of Inspector General (OIG) Compliance Guidance for Pharmaceutical Manufacturers and Pharmaceutical Research and Manufacturers of America (PhRMA) Code on Interactions with Medical Professionals. Additionally, <https://daiichisankyo.us/corporate-giving-and-support> provides information on criterion for submission, our process, and some Frequently Asked Questions.

Logistical questions regarding grant submissions can be submitted to [OGE-CME\\_US@daiichisankyo.com](mailto:OGE-CME_US@daiichisankyo.com) and will be channeled to the appropriate therapeutic area Grant manager. As always, we thank you for your contributions to continued education, professional development, and the ultimate elevation of best, personalized care for patients.

Sincerely,

The Medical Proficiency Acceleration Center team,

Daiichi Sankyo, Inc.